secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2022-11-15T23:59:59+00:00
Accession:  0001213900-22-072851
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics Q3 net loss of $5M; cash at $3.9M; substantial doubt about going concern
--------------------------------------------------------------------------------

- Cash $3.9M as of Sept 30, 2022, down from $19.6M at Dec 31, 2021.
- Net loss of $5.0M in Q3 2022 vs $1.4M in Q3 2021; R&D expense rose to $3.0M.
- Cash insufficient to fund operations beyond Dec 31, 2022; going concern warning issued.
- In discussions with Series A preferred holder for bridge loan; no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390022072851/0001213900-22-072851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390022072851/ea168752-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-072851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer